What changed today in Metabolic: 8 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
Weight-loss maintenance & regain
Research and practice on maintaining weight loss, and on weight regain after GLP-1 therapy is reduced or stopped.
Emerging
- Editorial attention
- Emerging
- Tracked this week
- 0
- Sources this week
- 0
- Last activity
- Nov 1, 2026
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Weight-loss maintenance & regain at a glance
- About this topic
- Research and practice on maintaining weight loss, and on weight regain after GLP-1 therapy is reduced or stopped.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Nov 1, 2026)
- Key facts from tracked records
- 5 NPHLA briefings on this topic
What’s the latest on Weight-loss maintenance & regain?
5 totalWhat changed today in Metabolic: 2 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records5 sources1 min read
What changed today in Metabolic: 3 trial updates, 2 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records8 sources1 min read
What changed today in Metabolic: 4 new studies, 3 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Metabolic: 9 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records12 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- New trial registered: ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation (opens the source in a new tab)
Not applicable, Affiliated Hospital to Academy of Military Medical Sciences. Conditions: Obesity & Overweight. Interventions: Endoscopic Radial Compression Gastroplasty (ERCG); Intensive Lifestyle Intervention (ILI). Investigational: trial-stage therapies are not approved for …
- New trial registered: Changes in Body Composition Following Pharmacological Treatment for Obesity. (opens the source in a new tab)
Hospital San Carlos, Madrid. Conditions: Obesity (BMI Equal to or >30); Weight Regain After Bariatric Surgery. Interventions: . Investigational: trial-stage therapies are not approved for the use studied.
- Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men (opens the source in a new tab)
- Weight Maintenance Following Discontinuation of Semaglutide in an Adolescent with Antipsychotic-Associated Weight Gain: A Case Report (opens the source in a new tab)
- Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial (opens the source in a new tab)
- New trial registered: Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and… (opens the source in a new tab)
Phase 4, General Committee of Teaching Hospitals and Institutes, Egypt. Conditions: Morbid Obesity. Interventions: Semaglutide weekly injection; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes (opens the source in a new tab)